{"id":"NCT00853658","sponsor":"Novartis Pharmaceuticals","briefTitle":"Efficacy and Safety of Aliskiren and Aliskiren/Enalapril Combination on Morbidity-mortality in Patients With Chronic Heart Failure","officialTitle":"A Multicenter, Randomized, Double-blind, Parallel Group, Active-controlled Study to Evaluate the Efficacy and Safety of Both Aliskiren Monotherapy and Aliskiren/Enalapril Combination Therapy Compared to Enalapril Monotherapy, on Morbidity and Mortality in Patients With Chronic Heart Failure (NYHA Class II - IV). The Study is Also Known as Aliskiren Trial of Minimizing OutcomeS in Patients With HEart Failure (ATMOSPHERE).","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2009-03","primaryCompletion":"2015-10","completion":"2015-10","firstPosted":"2009-03-02","resultsPosted":"2016-11-25","lastUpdate":"2016-11-25"},"enrollment":7064,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Chronic Heart Failure"],"interventions":[{"type":"DRUG","name":"Enalapril","otherNames":[]},{"type":"DRUG","name":"Aliskiren","otherNames":["SPP100"]}],"arms":[{"label":"Combination Aliskiren / Enalapril","type":"EXPERIMENTAL"},{"label":"Aliskiren","type":"EXPERIMENTAL"},{"label":"Enalapril","type":"ACTIVE_COMPARATOR"}],"summary":"The study will evaluate the efficacy and safety of both aliskiren monotherapy and aliskiren/enalapril combination therapy as compared to enalapril monotherapy, on morbidity and mortality in patients with chronic heart failure (NYHA Class II - IV.","primaryOutcome":{"measure":"Number of Participants That Had First Occurrence of the Composite Endpoint, Which is Defined as Either Cardiovascular (CV) Death or Heart Failure (HF) Hospitalization","timeFrame":"up to End of Study (78 months)","effectByArm":[{"arm":"Combination Aliskiren / Enalapril","deltaMin":770,"sd":null},{"arm":"Aliskiren","deltaMin":791,"sd":null},{"arm":"Enalapril","deltaMin":808,"sd":null}],"pValues":[{"comp":"OG000 vs OG002","p":"0.1724"},{"comp":"OG000 vs OG002","p":"0.4579"},{"comp":"OG001 vs OG002","p":"0.0368"},{"comp":"OG001 vs OG002","p":"0.9118"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":806,"countries":["United States","Argentina","Australia","Austria","Belgium","Brazil","Canada","China","Colombia","Costa Rica","Czechia","Denmark","Dominican Republic","Estonia","Finland","France","Germany","Greece","India","Ireland","Italy","Japan","Latvia","Lithuania","Mexico","Netherlands","Norway","Peru","Poland","Portugal","Puerto Rico","Romania","Russia","Slovakia","South Africa","South Korea","Spain","Sweden","Switzerland","Taiwan","Thailand","Turkey (TÃ¼rkiye)","United Kingdom","Venezuela"]},"refs":{"pmids":["38904251","37366061","34101002","33089502","32720404","31849164","31813280","29141857","29018174","28948656","27043774"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1466,"n":2347},"commonTop":["Hyperkalaemia","Hypotension","Renal impairment","Cough","Cardiac failure"]}}